Woodline Partners’s Trillium Therapeutics Inc. TRIL Stock Holding History

Woodline Partners’s Portfolio TRIL Stock Details TRIL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-139,907	Closed	-$2.46M	–	863
2021 Q3	$2.46M	Sell	139,907 -1,726,166	-93%	-$20.2M	0.04%	378
2021 Q2	$18.1M	Buy	1,866,073 +831,082	+80%	+$7.82M	0.34%	78
2021 Q1	$11.1M	Buy	1,034,991 +273,526	+36%	+$3.38M	0.25%	103
2020 Q4	$11.2M	Sell	761,465 -69,032	-8%	-$995K	0.3%	101
2020 Q3	$11.8M	Buy	830,497 +203,687	+32%	+$2.03M	0.39%	79
2020 Q2	$5.07M	Sell	626,810 -27,971	-4%	-$173K	0.2%	113
2020 Q1	$2.65M	Buy	+654,781	New	+$2.48M	0.19%	110

Other funds holding TRIL

Optiver Holding Amsterdam, Netherlands $289B AUM 33.63% 1-Year Est. Return

Woodline Partners's TRIL Position: Q4 2021 in Review

Woodline Partners sold out of Trillium Therapeutics Inc. (TRIL) in Q4 2021, closing a stake of 139,907 shares — an estimated $2.46M sold.

Woodline Partners first reported a position in TRIL in Q1 2020 and held it in 7 quarters. The position peaked at $18.1M in Q2 2021. 2 funds tracked by Wall St. Rank hold TRIL as of Q4 2021.

Woodline Partners reported no remaining Trillium Therapeutics Inc. position as of Q4 2021 after selling out during the quarter.
Woodline Partners sold 139,907 Trillium Therapeutics Inc. shares in Q4 2021, an estimated $2.46M.
Woodline Partners first reported a position in Trillium Therapeutics Inc. in Q1 2020 and held it in 7 quarters.
Woodline Partners's Trillium Therapeutics Inc. position peaked at $18.1M in Q2 2021.
2 funds tracked by Wall St. Rank held Trillium Therapeutics Inc. as of Q4 2021.

Based on Woodline Partners's 13F filing for Q4 2021, filed 14 Feb 2022.